News
Why Teradyne's 19% Rally Is Just Getting Started
The stock market often sends investors subtle hints, but on July 30, 2025, its message about Teradyne, Inc. (NASDAQ: TER) was loud and clear.
Shares of the semiconductor test equipment supplier
Ingredion Incorporated liefert solide Ergebnisse für das zweite Quartal und verbessert den Ausblick für das Gesamtjahr
- Ausgewiesenes und bereinigtes* Betriebsergebnis ist im zweiten Quartal 2025 gegenüber dem Vorjahr um 13 % bzw. 1 % gestiegen
- Ausgewiesene und bereinigter Gewinn pro Aktie belief sich im zweiten
Moderna Aktie: Herausforderung verpasst?
Moderna lieferte bessere Quartalszahlen als erwartet – doch das interessiert heute niemanden. Der Biotech-Konzern…
Der Beitrag Moderna Aktie: Herausforderung verpasst? erschien zuerst auf kapitalmar
Rocketing Volume: 3 Stocks With Big Potential Moves
It seems that trading the S&P 500 index lately has become an afterthought for most investors on Wall Street, especially considering how little volatility there has been recently to compress the
Exelixis Stock: Mixed Signals After Earnings Beat
Biotech company Exelixis delivered notably mixed second-quarter 2025 results, creating divergent investor reactions. The California-based firm reported earnings per share of $0.75, significantly
3 Value Stocks Flying Under the Radar—For Now
As a group, value stocks have tended to underperform their growth peers in recent quarters. This may position some companies in the value category as even more compelling, given that they may now
Europäische Kommission genehmigt IMBRUVICA® (ibrutinib) als erste zielgerichtete Therapie für Patienten mit zuvor unbehandeltem Mantelzell-Lymphom, die für eine autologe Stammzelltransplantation in Frage kommen
Ibrutinib ist der erste zugelassene Bruton-Tyrosinkinase-Inhibitor (BTKi), der statistisch signifikante Ergebnisse gegenüber der autologen Stammzelltransplantation (ASCT) bei der
PEGA Surges 14%: There's Still Time to Ride This GenAI Innovator
For the second quarter in a row, artificial intelligence (AI) tech stock Pegasystems (NASDAQ: PEGA) crushed expectations.
Shares soared 14% on July 22 as the company eclipsed Wall Street
Trinet Stock: Earnings Beat Despite Mixed Signals
California-based HR solutions provider TriNet reported second-quarter 2025 results that significantly exceeded analyst expectations, driving shares up 3.85% to $68.25 in pre-market trading. The
Booz Allen Hamilton Stock: Profit Surge Despite Revenue Miss
Booz Allen Hamilton's first quarter fiscal 2026 results painted a mixed picture, with the consulting firm's stock jumping nearly 5% to $120.85 despite slightly missing revenue expectations. While
Die Europäische Kommission genehmigt DARZALEX® (daratumumab) als erste zugelassene Behandlung für Patienten mit hochriskantem Schwelendem Multiplem Myelom (SMM)
Die entscheidende Genehmigung basiert auf den Ergebnissen der Phase III-Studie AQUILA, die zeigt, dass eine Behandlung mit daratumumab mit fester Behandlungsdauer das Risiko einer Progression zum
Moderna Aktie: Zielgerichteter Wachstumsschub!
Ein Durchbruch in der mRNA-Technologie hat Moderna schlagartig zurück auf die Radar der Anleger…
Der Beitrag Moderna Aktie: Zielgerichteter Wachstumsschub! erschien zuerst auf kapitalmarktexperten.d
Simmons First National Stock: Executives Invest $300K in New Shares
In a strong vote of confidence, multiple Simmons First National executives have collectively purchased approximately $300,000 worth of company shares during a public offering on July 23, 2025. The
Cathay General Stock: Earnings Beat Drives Growth Outlook
Cathay General Bancorp has narrowly surpassed market expectations in the second quarter of 2025, posting earnings per share of $1.10 against analyst projections of $1.09. The California-based
3 Bullish Biotech Stocks With Explosive Growth Trends
Investing in biotechnology stocks is similar to the drug development process itself. That is, investors frequently experience long periods of nothing much happening, interrupted by periods of
Aztiq verkauft Adalvo an EQT
- Adalvo wurde 2018 von Aztiq gegründet und ist eines der führenden Business-to-Business-Pharmaunternehmen in Europa.
- EQT wird Adalvo in der nächsten Wachstumsphase unterstützen, seine geografische
3 Streaming Stocks to Watch as Subscribers Drive Growth
The retail sales report for June showed a slight increase in consumer discretionary spending. One month doesn’t make a pattern, but it’s at least a temporary relief for companies that rely on
Is J.B. Hunt Stock a Sleeping Giant Heading Into 2026?
J.B. Hunt Transport Services' (NASDAQ: JBHT) stock price hit bottom earlier this year, setting it up for a significant reversal and potential gains over the next three to five years. The caveat
Unity’s New Ad Solutions Drive Stock to 52-Week High
Unity Software (NYSE: U) gave investors a reason to take notice in mid-July 2025. The company’s stock jumped over 14% to a new 52-week high. Unity’s stock price jump was powered by a trading
Insiders Spent Millions on These 3 Stocks Over the Past 2 Months
Since early May, insider buying activity has surged at three major companies. Together, top executives and influential insiders have invested more than $170 million of their own money, sending a
3 Fast Food Stocks That Won’t Give You Indigestion Right Now
Americans are no longer bellying-up to the counter at fast food establishments, and that’s giving industry executives indigestion.
Exhibit “A” is fast food stocks that are tapering off. Here’s a
These 2025 Outperformers Just Unlocked Buyback Fuel
Two stocks that are greatly outperforming the market in 2025 just signaled further confidence. They just announced big-time share buyback authorizations, providing both repurchase capacity equal
Analysts Upgrade Roku Stock: Can It Deliver and Go Beyond?
When it comes to finding upside in the stock market, investors are often better off doing their own homework and analysis. However, in markets like today’s, with technology stock valuations near
3 Infrastructure Stocks Riding the U.S. Building Boom
Infrastructure has been an investable theme ever since the U.S. Congress passed the Infrastructure Investment and Jobs Act (IIJA) in November 2021. At that time, opportunistic investors could have
Johnson & Johnson reicht bei der Europäischen Arzneimittel-Agentur einen Antrag auf Indikationserweiterung für AKEEGA® (niraparib und abirateronacetat-Doppeltablette) zur Behandlung von erwachsenen Patienten mit metastasiertem hormonsensitivem Prosta
Der Antrag basiert auf den Ergebnissen der Phase III-Studie AMPLITUDE, in der niraparib in Kombination mit abirateronacetat plus prednison oder prednisolon im Vergleich zur aktuellen